Novadaq Technologies Inc.TSX: NDQ

Novadaq reports financial results for third quarter of 2006

· Issued by Novadaq Technologies Inc. via CNW
TORONTO, Nov. 6 /CNW/ - Novadaq(R) Technologies Inc. (TSX: NDQ), a
developer of medical imaging systems for the operating room, today reported
its results for the third quarter ended September 30, 2006.
"The third quarter was an extremely busy and strategically successful
period for us. I am very proud of the milestones our team has achieved," said
Arun Menawat, President and Chief Executive Officer of Novadaq Technologies
Inc. "Since the beginning of July we have made significant advancements on a
number of key initiatives that will drive commercialization of our products.
These include a CMS recommendation made for a reimbursement code for the SPY
System, positive results from our clinical trial of the OPTTX System and
initiation of the clinical development for LUNA. We have now also received
regulatory approval to market OPTTX in Europe."

<<
Selected Third Quarter, 2006 Financial and Operating Highlights

-  SPY(R): Presented to Centers for Medicare & Medicaid Services (CMS)
   the federal agency responsible for administering the United States'
   health-related programs, resulting in a recommendation for a unique
   ICD-9-CM reimbursement code. Signed an exclusive European and Emerging
   Markets distribution agreement with Eastman Kodak Company for the SPY
   System. Announced the hiring of Jack Randle as Divisional Vice
   President, Sales for Novadaq's Cardiac Business to further enhance the
   commercialization of the SPY System.

-  OPTTX(R): Presented results from a clinical trial of 40 patients,
   demonstrating that, among other positive results, at the end of the
   treatment, on average the visual acuity was stable, and 29% of all
   patients seen at this visit had an improvement in vision. This
   percentage rose to 50% for those patients that followed the trial
   visit schedule. These results were a major factor in the receipt of
   the necessary CE Mark Certificates to market the OPTTX System in
   Europe.

-  LUNA(TM): Researchers from the University of Rochester won the award
   for Best Scientific Paper at the 24th World Congress of Endourology.
   The team submitted virtual posters in the areas of bladder cancer and
   testicular torsion visualization, as well as radical prostatectomy,
   for which their paper was recognized. Initiated first human clinical
   trial in Rochester on partial nephrectomy.
>>

Financial Results

Three Months Ended September 30, 2006 "Q3-2006" Compared to Three Months
Ended September 30 2005 "Q3-2005"

Revenue increased to approximately $532,000 in Q3-2006 from approximately
$222,000 in Q3-2005 including a five fold increase in procedural revenue
resulting from an increase in the installed base of SPY Systems. The capital
sale based revenue recorded in Q3-2006 related to the distribution agreement
with Kodak which was completed in September 2006 for Europe and Emerging
Markets. Procedure based revenue decreased to approximately $402,000 in
Q3-2006 from approximately $500,000 in Q2-2006 or by 20%. During the summer
months, 2 additional Spy Systems were placed, and SPY System utilization rates
during the summer months were also lower than in the second quarter of 2006.
Gross profit as a percentage of sales decreased to approximately 51% in
Q3-2006 from approximately 72% in Q3-2005. The difference relates primarily to
capital sales of SPY Systems completed in each period. The blended sales model
employed in Europe in 2006 involves lower capital sales prices and initial
gross profits on SPY Systems, and higher expected ongoing procedure based
revenue streams. Gross profit as a percentage of sales decreased from
approximately 58% in Q2-2006 to 51% in Q3-2006, primarily due to lower
utilization rates achieved during the summer months.
Sales and marketing expenses increased by approximately $798,000 to
approximately $1,134,000 in Q3-2006 from approximately $336,000 in Q3-2005 to
support the commercial launch of the SPY System in the US. Significant
increases included the cost of hiring 12 Clinical Educators, increased
commission expense, and increased marketing costs. Sales and marketing
expenses in Q3 2006 decreased slightly from Q2-2006.
Research and development expenses increased by approximately $362,000 to
approximately $1,164,000 in Q3-2006 from $802,000 in Q3-2005. The overall
increase relates primarily to increases in OPTTX System design and testing
costs. Research and development costs in Q3-2006 decreased slightly from
Q2-2006.
General and administration expenses increased to approximately $852,000
in Q3-2006 from $512,000 in Q3-2005, and from $675,000 in Q2-2006. The overall
increase over the entire period includes an increase in professional fees,
salaries, investor relations costs and insurance.
Depreciation expense increased to approximately $45,000 in Q3-2006 from
$6,000 in Q3-2005 and from approximately $40,000 in Q2-2006, primarily as a
result of additional computer hardware, software and other office equipment to
support the growth of the Company's infrastructure.
The Company had a total investment return of approximately $284,000 in
Q3-2006 on its cash and short-term investments, compared to $215,000 in
Q3-2005. The increase in investment returns over Q3-2005 is primarily the
result of higher interest rates.
Net loss increased by approximately $1,614,000 to approximately
$2,741,000 in Q3-2006 from approximately $1,128,000 in Q3-2005 primarily as a
result of an increase in sales and marketing costs of approximately $798,000,
an increase in research and development expenses of approximately $362,000, an
increase in general and administrative expenses of approximately $340,000, and
a reduction in foreign exchange gain of approximately $254,000, offset
partially by an increase in investment returns of approximately $69,000. Net
loss increased in Q3-2006 by approximately $129,000 from Q2-2006 due to
increased general and administrative expenses.

Nine Months Ended September 30, 2006 "YTD-2006" Compared to Nine Months
Ended September 30 2005 "YTD-2005"

Revenue in YTD 2006 was approximately $1,559,000, or 353% of YTD 2005
revenue of approximately $442,000. This included an increase in procedure
based revenue from approximately $155,000 to approximately $1,232,000 due
primarily to the increasing installed based in the US.
Sales and marketing expenses increased to approximately $3,088,000 in YTD
2006 from approximately $739,000 in YTD 2005 primarily due to the expansion of
commercialization activities in the US.
Research and development expenses increased to approximately $3,789,000
in YTD 2006 from approximately $2,469,000 in YTD 2005 primarily due to
increases in salary expense for engineering staff hired to increase product
development capacity, clinical and regulatory staff to accelerate OPTTX and
LUNA programs, expenses associated with the SPY patient registry and visionary
programs, and patent and trademark costs incurred to protect developments in
OPTTX and LUNA, and expanded applications of SPY.
General and administration expenses decreased from approximately
$2,201,000 in YTD 2005 to approximately $2,094,000 in YTD 2006 primarily as a
result of a significant reduction in stock based compensation expense which
was unusually high in YTD-2005 due to the contractual vesting of all pre-2005
options upon the initial public offering completed in June 2005. The reduction
in stock based compensation was mostly offset by general increases in
administrative costs to support the commercial launch of SPY in the US, and
public company costs.
As at September 30, 2006 the Company had cash, cash equivalents and
short-term investments of approximately $19,976,000, a decrease of
approximately $2,799,000 from December 31, 2005. The decrease was primarily
the result of the cash used in operations of approximately $6,321,000, and
cash invested in property and equipment and licenses of approximately
$1,926,000, offset partly by proceeds of approximately $5,463,000 from the
exercise of warrants in YTD-2006.
As at September 30, 2006 there were a total of 19,709,561 common shares
(21,449,872 on a fully diluted basis) and no preferred shares outstanding.

Conference call

Novadaq will host a conference call and live webcast on Monday,
November 6, 2006 at 4:30 p.m. E.T. to discuss its third quarter 2006 results.
To access the conference call by telephone, dial 416-644-3414 or
1-800-814-4862. Please connect approximately ten minutes prior to the
beginning of the call to ensure participation. The conference call will be
archived for replay until November 13, 2006 at midnight. To access the
archived conference call, dial 416-640-1917 or 1-877-289-8525 and enter the
reservation number 21208114 followed by the number sign.
A live audio webcast of the conference call will be available at
www.novadaq.com. Please connect at least ten minutes prior to the conference
call to ensure adequate time for any software download that may be required to
join the webcast. The webcast will be archived at the above website for 90
days.

About Novadaq Technologies

Novadaq Technologies Inc. (TSX: NDQ) develops and commercializes medical
devices based on its proprietary imaging platform for the diagnosis and
treatment of human vascular and ophthalmic diseases and conditions. Novadaq's
SPY Intra-operative Imaging System, commercially available worldwide, enables
cardiac surgeons to visually assess coronary vasculature and bypass graft
functionality during the course of open-heart surgery. Novadaq's ophthalmic
product, the OPTTX System, is aimed at the diagnosis, evaluation and treatment
of wet Age-related Macular Degeneration (AMD) by using the same core imaging
technology that is used in the SPY System. Novadaq received CE Mark approval
for the OPTTX System in November 2006 and expects a limited launch in Europe
by year end. Novadaq's product for urology, LUNA is designed to enable
surgeons to visualize nerve bundles during the course of urological procedures
such as radical prostatectomy in order to reduce negative outcomes including
impotency. For more information, please visit the company's website at
www.novadaq.com.

This press release contains certain information that may constitute
forward-looking information within the meaning of securities laws. In some
cases, forward-looking information can be identified by the use of terms such
as "may", "will", "should", "expect", "plan", "anticipate", "believe",
"intend", "estimate", "predict", "potential", "continue" or other similar
expressions concerning matters that are not historical facts. Forward-looking
information may relate to management's future outlook and anticipated events
or results, and may include statements or information regarding the future
financial position, business strategy and strategic goals, research and
development activities, projected costs and capital expenditures, financial
results, research and clinical testing outcomes, taxes and plans and
objectives of or involving Novadaq. Without limitation information regarding
future sales and marketing activities, SPY System placement targets and
utilization rates, the implementation of a reimbursement code for the SPY
System, future revenues and research and development activities, and the
planned European commercial launch of the OPTTX System, as well as the
Company's plans for each of the SPY System, the OPTTX System and LUNA, is
forward-looking information.
Forward-looking information is based on certain factors and assumptions
regarding, among other things, market acceptance and the rate of market
penetration of Novadaq's SPY System, the effect of a recommended reimbursement
code for the SPY System, the clinical results of the use of the SPY System,
the results from clinical tests of the OPTTX System and LUNA , and potential
opportunities in the AMD treatment market and in image guided conventional and
minimally invasive urological applications including nerve-sparing radical
prostatectomy. While the Company considers these assumptions to be reasonable
based on information currently available to it, they may prove to be
incorrect.
Forward looking-information is subject to certain factors, including
risks and uncertainties that could cause actual results to differ materially
from what we currently expect. These factors include risks relating to the
transition from research and development activities to commercial activities,
market acceptance and adoption of the SPY System and of the OPTTX System, the
risk that a recommended reimbursement code will not be fully implemented or
that it will not affect acceptance of the SPY System, risks related to third
party contractual performance, dependence on key suppliers for components of
the SPY System and the OPTTX System, regulatory and clinical risks, risks
relating to the protection of intellectual property, risks inherent in the
conduct of research and development activities, including the risk of
unfavorable or inconclusive clinical trial outcomes, potential product
liability, competition and the risks posed by potential technological
advances, and risks relating to fluctuations in the exchange rate between the
US dollar and the Canadian dollar.
You should not place undue importance on forward-looking information and
should not rely upon this information as of any other date. While Novadaq may
elect to, Novadaq is under no obligation and does not undertake to update this
information at any particular time.
This press release was prepared by management from information available
to November 3, 2006.

Summary financial statements attached:

For complete financial statements please go to www.sedar.com



<<
                      NOVADAQ TECHNOLOGIES INC.
                Incorporated under the laws of Canada

                           BALANCE SHEETS
                         (expressed in U.S.$)
                              Unaudited


                                                  As at         As at
                                              September 30,  December 31,
                                                   2006          2005
                                                     $             $
-------------------------------------------------------------------------

                               ASSETS

Current
Cash and cash equivalents                          413,581       750,726
Short-term investments                          19,562,000    22,023,537
Accounts receivable                                226,893       233,977
Investment tax credits receivable                    5,214        41,341
Prepaid expenses and other receivables             501,667       553,534
Inventory                                          257,429       410,064
-------------------------------------------------------------------------
Total current assets                            20,966,784    24,013,179
-------------------------------------------------------------------------
Property, plant and equipment, net               1,983,337       464,484
Deferred charges                                     5,442        11,259
Licenses, net                                    2,716,795     3,030,711
-------------------------------------------------------------------------
                                                25,672,358    27,519,633
-------------------------------------------------------------------------
-------------------------------------------------------------------------

                 LIABILITIES AND SHAREHOLDERS' EQUITY

Current
Accounts payable and accrued liabilities         1,651,507     1,432,455
Current portion of deferred revenue                 31,126        37,351
-------------------------------------------------------------------------
Total current liabilities                        1,682,633     1,469,806
-------------------------------------------------------------------------
Deferred revenue                                         -        21,789
-------------------------------------------------------------------------
Total liabilities                                1,682,633     1,491,595
-------------------------------------------------------------------------

Shareholders' equity
Share capital                                   51,719,132    46,255,988
Contributed surplus                              3,638,508     3,411,851
Deficit                                        (31,367,915)  (23,639,801)
-------------------------------------------------------------------------
Total shareholders' equity                      23,989,725    26,028,038
-------------------------------------------------------------------------
                                                25,672,358    27,519,633
-------------------------------------------------------------------------
-------------------------------------------------------------------------



                      NOVADAQ TECHNOLOGIES INC.

                   STATEMENTS OF LOSS AND DEFICIT
                        (expressed in U.S.$,)
                              Unaudited


                          Three months ended       Nine months ended
                            September 30,             September 30,
                          2006         2005         2006         2005
                            $            $            $            $
-------------------------------------------------------------------------

Revenue                   531,805      222,425    1,559,291      441,900
Cost of sales             261,166       62,798      759,073      140,369
-------------------------------------------------------------------------
Gross profit              270,639      159,627      800,218      301,531
-------------------------------------------------------------------------

Operating expenses
Sales and marketing     1,133,956      336,024    3,088,197      738,644
Research and
 development            1,163,750      801,870    3,788,912    2,469,443
General and
 administration           851,603      511,727    2,093,712    2,200,873
Depreciation               45,021        5,947      122,631       17,915
Amortization              109,660      109,472      328,916      321,435
Loss (gain) on
 foreign exchange          (7,935)    (263,343)     (84,456)    (474,697)
-------------------------------------------------------------------------
                        3,296,055    1,501,696    9,337,912    5,273,613
-------------------------------------------------------------------------
Loss before the
 following             (3,025,416)  (1,342,070)  (8,537,694)  (4,972,082)
Other income                    -            -       60,896            -
Interest income           284,345      215,249      748,684      339,724
-------------------------------------------------------------------------
Net loss for the
 period                (2,741,071)  (1,126,821)  (7,728,114)  (4,632,358)

Deficit, beginning
 of period            (28,626,845) (20,270,880) (23,639,801) (16,765,343)
-------------------------------------------------------------------------
Deficit, end of
 period               (31,367,916) (21,397,701) (31,367,915) (21,397,701)
-------------------------------------------------------------------------
-------------------------------------------------------------------------

Basic and diluted
 loss per share             (0.14)       (0.06)       (0.40)       (0.28)
-------------------------------------------------------------------------
-------------------------------------------------------------------------



                      NOVADAQ TECHNOLOGIES INC.

                      STATEMENTS OF CASH FLOWS
                        (expressed in U.S.$)
                              Unaudited


                          Three months ended       Nine months ended
                            September 30,             September 30,
                          2006         2005         2006         2005
                            $            $            $            $
-------------------------------------------------------------------------

OPERATING ACTIVITIES
Net loss for
 the period            (2,741,071)  (1,126,821)  (7,728,114)  (4,632,358)
Add (deduct) items
 not involving cash
  Depreciation and
   amortization           279,613      131,932      736,234      367,239
  Stock based
   compensation            81,825       34,500      226,657    1,103,440
-------------------------------------------------------------------------
                       (2,379,633)    (960,389)  (6,765,223)  (3,161,679)
Net change in non-cash
 working capital
 balances related
 to operations            137,152     (654,599)     444,568      852,875
-------------------------------------------------------------------------
Cash (used) in
 operating activities  (2,242,481)  (1,614,988)  (6,320,655)  (2,308,804)
-------------------------------------------------------------------------

FINANCING ACTIVITIES
Issuance of common
 shares                       837        2,700    5,463,144   18,250,323
-------------------------------------------------------------------------
Cash provided by
 financing activities         837        2,700    5,463,144   18,250,323
-------------------------------------------------------------------------

INVESTING ACTIVITIES
Purchase of property,
 plant and equipment     (409,087)    (171,113)  (1,926,171)    (273,776)
Purchase of licenses            -            -      (15,000)    (125,000)
Investments in
 short-term inv.,net    2,992,767    1,807,736    2,461,537  (15,795,519)
-------------------------------------------------------------------------
Cash provided by
 (used in) investing    2,583,680    1,636,623      520,366  (16,194,295)
-------------------------------------------------------------------------

Net increase
 (decrease) in cash
 and cash equivalents
 during the period        342,036       24,335     (337,145)    (252,776)
Cash and cash equiv.
 beginning of period       71,545      157,269      750,726      434,380
-------------------------------------------------------------------------
Cash and cash
 equivalents, end
 of period                413,581      181,604      413,581      181,604
-------------------------------------------------------------------------
-------------------------------------------------------------------------
>>
%SEDAR: 00022069E

Novadaq Technologies Inc. on 6ix

Story so far

Earlier from Novadaq Technologies

Later from Novadaq Technologies

All Novadaq Technologies news releases